Abstract
Diabetic macular edema (DME), a common microvascular complication of diabetes mellitus (DM), may negatively affect visual acuity (VA), leading to blindness. Timely diagnosis and treatment may improve outcomes. This study was based on the hypothesis that treatment with ranibizumab (alone or with laser) would show greater improvement in best-corrected VA than laser alone. Eligible patients had stable DM (HbA1c ≤10.0% at baseline), and visual impairment (VI) due to DME deemed eligible for laser treatment. Two hundred forty-one participants were randomized 1:1:1 to ranibizumab (n=81), laser (n=82) or combination treatment (n=78). For combination and monotherapy, ranibizumab was administered as 3 monthly injections, then 10 months prn injections given/withheld based on DME stability criteria. Laser was administered per ETDRS guidelines at intervals ≥3 months. At baseline, the ITT population (n=235) had a mean (± SD) age of 62 (±9.8) years, was 61% male, 86% Caucasian and 86% had type 2 diabetes. Mean time since diagnosis was 17 (±10.1) years for diabetes and 1.7 (±2.7) years for DME. Twelve percent of the laser arm (n=82) was discontinued due to unsatisfactory therapeutic effect; 10% of safety patients (n=237) experienced an SAE. No deaths were reported.Tabled 1Mean Change from Baseline to Month 12CombinationRanibizumabLaserBCVA (ETDRS letters)8.08.70.895% CI(5.9, 10.1)(6.9, 10.5)(–2.2, 3.8)n747667CRT (μm)–145.2–134.7–103.695% CI(–178.4, –112.1)(–167.3, –102.0)(–138.7, –68.5)n747665 Open table in a new tab Preliminary analysis shows ranibizumab (alone or combination) is an effective and safe treatment for VI due to DME.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.